Dabrafenib
An oral BRAF kinase inhibitor that blocks the mutated BRAF V600E/K protein driving tumor growth in melanoma and certain other cancers. It is often combined with the MEK inhibitor trametinib to delay the development of resistance.
Masse moléculaire
519,6000 g/mol
LogP
4,80
TPSA
147,00 Ų
Règle des 5 de Lipinski
Non conforme
Aires thérapeutiques
Mécanisme d'action
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.
Structure 2D
Cite this structure
Embed this structure
SMILES
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
InChI
InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)
Molecular Formula
C23H20F3N5O2S2
HBD / HBA
2 / 11
Liaisons Rotatives
6
Atomes Lourds
35
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
An oral BRAF kinase inhibitor that blocks the mutated BRAF V600E/K protein driving tumor growth in melanoma and certain other cancers. It is often combined with the MEK inhibitor trametinib to delay the development of resistance.
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.
Yes, Dabrafenib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2028663. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 44462760. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="dabrafenib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/dabrafenib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/dabrafenib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/dabrafenib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="dabrafenib"></drugfyi-drug>